$5.77
+0.09 (+1.58%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ZURA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 5 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, MILLENNIUM MANAGEMENT LLC, Squarepoint Ops LLC) · FINRA short interest 19.6 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)NCT06843239[Period 1] Change from baseline in modified Rodnan Skin Score (mRSS) at 24 weeksRandomized · Triple-masked · Treatment | Phase 2 | Active, not recruiting | Biological: Tibulizumab · Other: Placebo | Systemic Sclerosis (SSc), Scleroderma | 80 | May 2027 | ≤ 285 d | 2026-07-20 |
| Tibulizumab Skin Healing and Inflammation Evaluation for Lasting DefenseNCT06993610[Period 1] Percent change from baseline in abscess and inflammatory nodule (AN) count at 16 weeksRandomized · Triple-masked · Treatment | Phase 2 | Active, not recruiting | Biological: Tibulizumab Dose A, Tibulizumab Dose B · Other: Placebo | Hidradenitis Suppurativa (HS) | 225 | Nov 2026 | ≤ 103 d | 2026-06-30 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19